Answers are grounded in this paper and cite their sources.
Osteosarcoma (OS) is an aggressive bone malignancy characterized by early metastatic propensity and poor prognosis. Current standard treatments (surgical resection combined with chemotherapy) are severely constrained by high recurrence rates and pulmonary metastasis, underscoring an urgent need for innovative precision theranostic strategies. Herein, we propose a “side chain‐acceptor dual‐driven” molecular engineering strategy to develop multifunctional second near‐infrared (NIR‐II) aggregation‐induced emission (AIE) phototheranostic agents. Through the systematic construction, comprehensive experimental and theoretical interrogation of a nine‐member AIEgen library, we establish definitive structure–property relationships that govern their photophysical behavior. The optimized candidate DFSQ‐OTPA comprise a novel difuran‐substituted selenadiazoloquinoxaline acceptor, which synergistically endows the system with intense long‐wavelength NIR‐II emission, exceptional photothermal conversion efficiency, and favorable reactive oxygen species (ROS) generation capability. Guided by NIR‐II fluorescence and photoacoustic dual‐modal imaging, DFSQ‐OTPA NPs achieve complete in situ ablation of orthotopic OS upon 808 nm laser irradiation, while concurrently and effectively suppressing pulmonary metastasis, all with an excellent biosafety profile. This study not only establishes a versatile design paradigm for high‐performance NIR‐II AIEgens but also provides a robust and translatable theranostic platform for OS management.
No takes yet. Share an insight, caveat, or question.
Zhou et al. (2026) studied this question.
Synapse has enriched 10 related papers. Consider them for comparative context: